The immunogenicity of tumors, such as breast cancer, reflects circumvention of tolerance to self-antigens. Increased understanding of how tolerance to self-antigens can be overcome has generated great interest in using immunotherapeutic approaches to prevent and eradicate breast malignancy. 1 One tumor-associated antigen in which there has been considerable interest is HER2/neu, a self-antigen overexpressed on many adenocarcinomas, including up to 30% of breast malignancies. 2,3 HER2/neu overexpression results from amplification and transcriptional upregulation of the c-erbB-2/neu proto-oncogene and is functionally important in tumor development and growth. In some subsets of breast cancer, HER2/neu overexpression correlates with a poorer prognosis. 4 T-cell-mediated immunity directed against HER2/neu also exists in patients with HER2/neu-overexpressing cancer, suggesting that immunomodulatory intervention to enhance this immunity is possible. 5-7 Our laboratory is actively investigating the immunologic response to HER2/neu following vaccination with peptide-based vaccines. 8,9 In addition to the potential role of a vaccine in protection against subsequent tumor growth, these antigen-specific T cells could represent a source of cells for ex vivo expansion and ultimate use in adoptive T-cell-based immunotherapies targeting breast cancer (Figure 1 The identification and characterization of tumor antigens has facilitated the development of immune-based cancer prophylaxis and therapy. Cancer vaccines, like viral vaccines, may be effective in cancer prevention. Adoptive T-cell therapy, in contrast, may be more efficacious for the eradication of existing malignancies. Our group is examining the feasibility of antigen-specific adoptive T-cell therapy for the treatment of established cancer in the HER2/neu model. Transgenic mice overexpressing rat neu in mammary tissue develop malignancy, histologically similar to human HER2/neu-overexpressing breast cancer. These mice can be effectively immunized against a challenge with neu-positive tumor cells. Adoptive transfer of neu-specific T cells into tumor-bearing mice eradicates malignancy. Effective T-cell therapy relies on optimization of the ex vivo expansion of antigen-specific T cells. Two important elements of ex vivo antigen-specific T-cell growth that have been identified are (1) the preexisting levels of antigen-specific T cells and (2) the cytokine milieu used during ex vivo expansion of the T cells. Phase I clinical trials of HER2/neu-based peptide vaccination in human cancer patients have demonstrated that increased levels of HER2/neu-specific T cells can be elicited after active immunization. Initiating cultures with greater numbers of antigen-specific T cells facilitates expansion. In addition, cytokines, such as interleukin-12, when added during ex vivo culturing along with interleukin-2 can selectively expand antigen-specific T cells. Interleukin-12 also enhances antigen-specific functional measurements such as interferon-gamma and tumor necrosis factor-alpha release. Refinements in ex vivo expansion techniques may greatly improve the feasibility of tumor-antigen T-cell-based therapy for the treatment of advanced-stage HER2/neu-overexpressing breast malignancy.
Methods

Immunization, Tumor Challenge, and AntigenSpecific Adoptive T-Cell Therapy in the neuTransgenic Mouse Model
The intracellular domain (ICD) peptide-based vaccine consisted of the rat neu peptides spanning the amino acid positions 781-795, 788-802, 932-948, and 1171-1185. These peptides were predicted to elicit neu-specific T-cell immunity. 10 The neu-transgenic (neu-Tg) mice were immunized with peptides at a final concentration of 100 µg each in a total volume of 200 µL, including adjuvant. The animals underwent two immunizations 14-16 days apart. Control animals received adjuvant alone. Mice were challenged with tumor at indicated times using subcutaneous injection of 2 x 10 6 purified syngeneic tumor cells derived from spontaneously occurring mammary tumors. T cells used for adoptive transfer were derived from spleen of control mice or mice that had been previously vaccinated with the ICD peptidebased vaccine. These T cells were either used directly or cultured for 10 days in the presence of the same peptides used for vaccination with periodic additions of interleukin-2 (IL-2).
Patient Vaccinations
Patients were enrolled into a Food and Drug Administration-approved phase I clinical trial evaluating the toxicity and immunogenicity of a HER2/neu peptide-based vaccine, as previously described. 9 Briefly, the patients were immunized monthly for 6 months with a HER2/neu peptide vaccine consisting of putative HER2/neu peptides spanning the amino acids 369-384, 688-703, and 971-984. Each peptide contained within its sequences the human leukocyte antigen (HLA)-A2 binding peptides, p369-377, p689-697, and p971-979, respectively.
Generation and Expansion of Human T-Cell Lines and Clones
Antigen-specific T-cell lines and clones were generated by culturing patient peripheral blood mononuclear cells (PBMC) in the presence of HER2/neu peptide, as previously described. 9 Briefly, for the generation and expansion of HER2/neu-specific T-cell lines, PBMCs were cultured in 1 µM each of the HER2/neu HLA-A2 peptide, p369-377. For cloning, the T-cell lines were diluted to achieve approximately 0.3 viable cells/ 200 µL and plated onto 96-well plates in culture medium. Peptide-pulsed, irradiated autologous PBMCs (2.0 x 10 5 ) were added to each well in the presence of IL-2. The clones were eventually expanded and carried using IL-2 and peptidepulsed, irradiated autologous Epstein-Barr virus (EBV)-transformed B-lymphoblastic cells (BLCL).
Chromium-Release Assays
Cytolytic activity was measured using standard chromiumrelease assays. Targets used were peptide-pulsed BLCLs, which were labeled with chromium-51 for 1-2 hours prior to use. Killing of target cells is detected as the release of chromium-51. The cytolytic reaction was carried out for 4 hours at 37 o C, after which the amount of chromium-51 released into the cell culture media was assessed.
Enzyme-Linked Immunosorbent Spot
An enzyme-linked immunosorbent spot (ELIspot) assay was used to determine frequencies of peptide-specific CD8 T 
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Differences in the Clinical Role of Cancer Vaccines vs. Adoptive T-Cell Therapy
It is our view that the major role of cancer vaccines likely lies in the cancer prevention rather than as a treatment modality in eradicating established malignancy. This is analogous to viral vaccines, which are administered as a prophylactic to prevent disease (eg, influenza) but not to cure it. This observation can be illustrated in an animal model of breast cancer. The neu-Tg mouse is an FVB mouse strain genetically engineered to overexpress rat neu specifically in mammary tissue. 12 Female mice spontaneously develop mammary tumors after a long latency that histologically resembles human breast carcinoma, including neu overexpression. In these transgenic mice, rat neu is a selfantigen. In previous studies, we identified several putative major histocompatibility complex (MHC) class II binding helper peptides of rat neu 10 and found that immunization of rats with neu peptides elicited neu-specific T-cell immunity in vivo. These peptides were then used for immunization in the neu-Tg mouse model, where it was also observed that mice developed neu-specific T-cell responses. In tumor protection studies, we observed that two vaccinations with neu peptides, derived from the ICD, were adequate for efficient rejection of tumor cells implanted subcutaneously after immunization ( Figure 2A ). In contrast, the mice were unable to reject tumor if vaccination was begun concurrently with tumor inoculation ( Figure 2B ). Thus, vaccination protects neu-Tg mice against future tumor challenge.
The primary purpose of adoptive T-cell therapy is to augment T-cell responses over and above that achievable by vaccination alone. 13 Vaccination itself can increase the number of immune T cells capable of recognizing and responding to antigen. While repeated vaccination increases the number of immune effectors, eventually a plateau is reached after which further immunizations have little to no impact in further increasing the number of tumor-specific T cells. 13 Adoptive T-cell therapy allows levels of immunity to be achieved that could potentially mediate an antitumor response, and adoptive transfer of T cells can result in the infused cells representing a large fraction (eg, 1/2) of the host's lymphocytes. 13 Although the efficacy of administering high numbers of T cells to treat cancer in animal models is well established, in humans such attempts have met with limited success. 6 tumor cells on the same day immunizations with neu ICD peptides were initiated (day 0). Despite two immunizations, at 14-day intervals (arrows; day 0 and day 14), mice were unable to reject tumor. Both panels show data as the mean of tumor dimensions.
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tic lymphoma, and Hodgkin's disease. [14] [15] [16] In those studies, EBV-specific cytotoxic T lymphocytes (CTL) generated ex vivo and subsequently reinfused into patients were effective in both prophylaxis and the treatment of disease. Furthermore, the infused CTLs persisted for long periods while maintaining their antiviral properties. However, the major distinction between the treatment of EBV malignancies and nonviral cancers is the presence of nonself viral antigens. In nonviral cancers, tolerance-mediated deletion of potent and robust T cells has occurred to some extent and makes the ex vivo generation of an adequate antigen-specific T-cell population a challenge. One way to overcome this challenge is to vaccinate against antigen before retrieving T cells from the patient for expansion. Vaccination can increase the number of antigen-specific T cells in vivo.
To understand more fully eradication of HER2/neu-overexpressing breast cancer by adoptive T-cell therapy, we initiated studies using the neu-Tg mice. The data suggest that the transfer of neu-specific splenocytes from neu peptideimmunized neu-Tg mice into nonimmunized naive mice can eradicate preestablished neu-overexpressing mammary tumors (Figure 3) . The ability of the splenocytes to kill tumor was greatly enhanced by increasing the number of tumor-specific T cells with cell culture (ie, ex vivo enrichment) prior to reinfusion. In contrast, splenocytes derived from naive neu-Tg mice were unable to prevent tumor growth, demonstrating that prior immunization of the animals was necessary to mediate the response. Therefore, a hurdle to overcome for human clinical trials of adoptive T-cell therapy is the development of techniques for ex vivo expansion of HER2/neu-specific T cells.
Ex Vivo Expansion of Antigen-Specific T Cells
The requirements for the ex vivo expansion of T cells that would allow the generation of a maximal number of antigenspecific T cells while retaining optimal antigen-specific function are not well understood. Two of the most important obstacles are (1) a low preexisting antigen-specific T-cell precursor population and (2) lack of an appropriate in vitro cytokine environment. 13 The preexisting systemic level of antigen-specific T cells is important in culturing T cells. In unprimed individuals, the ex vivo expansion of HER2/neu antigen-specific T cells from peripheral blood is difficult because levels of these antigenspecific T cells can be extremely low. For example, isolation and expansion of HER2/neu-specific T cells from patients with HER2/neu-overexpressing breast or ovarian carcinomas is laborious and involves lengthy expansion techniques with multiple in vitro stimulations. 6 Therefore, in order to establish T-cell lines of sufficient antigen-specificity from unprimed individuals, one would have to start by culturing very large numbers of PBMCs. 17 One strategy to improve expansion is to increase the frequency of antigen-specific precursors in vivo prior to ex vivo Table 1 Preimmunization p369-377 9-mer Expansion of HER2/neu-Specific T Cells expansion by vaccination. Studies from our group have shown that boosting HER2/neu precursor frequencies by peptide immunization has allowed us to more readily expand and clone HER2/neu-specific T cells from the peripheral blood of patients with HER2/neu-overexpressing breast cancers as compared to naive donors (K. Knutson, unpublished observations).
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HER2/neu Peptide Immunization Results in Increased HER2/neu T-Cell Precursors
Phase I clinical trials were initiated in 1997 to assess both toxicity and immunogenicity of HER2/neu peptide-based vaccines in patients with stage III or IV breast or ovarian cancer. All of the vaccine formulations target HER2/neu peptides in either the ICD, extracellular domain (ECD), or both. 2 Granulocyte-macrophage colony-stimulating factor was used as an adjuvant, 18 and the immunizations were administered intradermally monthly for 6 months. The initial trial tested three helper T-cell vaccines, each composed of three MHC class II binding peptides, 15-18 amino acids in length. 2,9 One of the vaccine preparations (HLA-A2 vaccine) consisted of three putative T-helper epitopes of HER2/neu, each of which contains a complete HLA-A2 binding motif within their sequence. Vaccines using this strategy have been demonstrated to elicit both helper and cytolytic T-cell immunity. 9 Recently, the analysis of the 19 patients who received the HLA-A2 vaccine was reported. 9 In that study, it was observed that the majority of patients developed both HER2/ neu peptide-and protein-specific immunity. Despite generating significant levels of immunity, the HER2/neu vaccine was well tolerated. Detection of HER2/neu-specific T cells was assessed using an IFN-γ-ELIspot assay, which has been shown to be a reliable method to detect antigen-specific T cells existing in the peripheral blood at levels as low as 1 in 100,000 mononuclear cells. We demonstrated that T cells specific for HER2/neu were increased following vaccination 9 (Table 1) , allowing us to more readily expand functional T cells in the presence of antigen (Figure 4) .
The antigen-specific expansion of the T cells also enriches the cytolytic activity against HER2/neu ( Figure 5 ). Furthermore, increased T-cell precursors facilitate isolation of T-cell clones. For example, we isolated 21 p369-377 peptide-specific clones from an HLA-A2 patient immunized with the HLA-A2 vaccine. 19 Most of the clones (19 of 21) expressed the broad T-cell marker, CD3. While 11 of the clones expressed CD8 + (cytolytic T cells), nine expressed CD4 + (helper T cells) despite being cloned with the HLA-A2-binding 9-mer. Since 9-mer peptides in association with HLA-A predominantly regulate CD8 + T cells, the significance of CD4 + T cells responding to HLA-A2 9-mer is not well understood. Also, 19 of the clones expressed the alpha-beta T-cell receptor, and interestingly, two expressed the gamma-delta T-cell receptor. 20 The cytokine environment needed to expand a functional antitumor population and sustain it in vivo has been elucidated to some degree. 13 For example, IL-2, when added during in vitro stimulation of T cells, promotes proliferation and increased survivability of cells in vivo. 13 However, IL-2 activates T-cell lines nonspecifically and often antigen specificity is not preserved. We have found that IL-12, when added along with IL-2, enhances both expansion and function of HER2/neu-specific T-cell lines. 21 For example, IL-12 plus IL-2 enhances HER2/neu-specific tumor necrosis factoralpha release up to sixfold greater than that observed with IL-2 only following in vitro stimulation with HER2/neu peptides. Over the past decade, other T-cell-active cytokines, such as IL-4, IL-7, and IL-15, have been identified, which may exhibit similar in vitro activities (Table 2) . 13, [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] Studies are ongoing in our laboratory to characterize these cytokines for their utility in ex vivo expansion of HER2/neu-specific T cells.
Conclusions
Tumor antigen-targeted T-cell-based therapy is a feasible treatment strategy for HER2/neu-overexpressing malignancies. Vaccination alone most likely will not be effective as a treatment strategy for established disease but rather in preventing the recurrence of micrometastatic disease. Treatment of established disease will require T-cell therapy with ex vivo-expanded tumor-specific T cells. The use of vaccination followed by carefully manipulated ex vivo antigenmediated expansion of T cells offers the potential of increasing tumor-specific T cells to numbers greater than that which could be achieved by vaccination alone. Ex vivo expansion has been problematic and many hurdles will need to be overcome. Two important issues are (1) increasing antigenprimed T cells in vivo prior to ex vivo expansion by vaccination and (2) improved culture conditions with the use of recently identified cytokines in conjunction with IL-2. The refinement of techniques for antigen-specific T-cell therapy has ushered in a new era for the treatment of breast cancer.
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